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Abstract
 
To investigate the fundamental nature of protective immunity to 
 
Bordetella pertussis
 
, we studied
intranasal immunization of adult mice with formalin-fixed 
 
B. pertussis
 
 (FFBP), followed by
aerosol 
 
B
 
.
 
 pertussis 
 
challenge. Mice given two doses of FFBP intranasally completely cleared a
subsequent pertussis aerosol challenge from tracheae and lungs (defined as protection), but
there was no correlation between levels of specific antibody and clearance of bacteria. Further,
transfer of immune serum before aerosol challenge had minimal effects on bacterial burdens.
However, pertussis-specific T cells producing interferon 
 
g 
 
but not interleukin 4 or interleukin
10 were detected in draining lymph nodes of FFBP-immunized mice. Significantly, repeated
immunization of B cell knockout (BKO) mice resulted in partial protection, and complete pro-
tection was reconstituted by transfer of pertussis-immune B cells; reconstituted BKO mice had
little if any detectable antipertussis antibodies. Immunization of mice lacking all T cells or lack-
ing CD4
 
1
 
 T cells did not lead to protection; in contrast, CD8
 
2
 
 mice were protected. Mice de-
pleted of CD4
 
1
 
 T cells after immunization but before aerosol challenge, which thus had nor-
mal amounts of specific antibodies, were not optimally protected. Taken together, these data
indicate that protective immunity to pertussis is dependent on both CD4
 
1
 
 T cells and B cells,
and both cell types provide significant functions other than specific antibody production.
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Introduction
 
Bordetella pertussis
 
 is a gram-negative bacterium that typi-
cally infects mammals through inhalation, establishing a
respiratory infection in the nasopharynx, trachea, and
bronchial tree of the lungs (1). The resulting disease,
whooping cough, is associated with significant morbidity
and mortality in children worldwide; adult disease is gen-
erally milder, but adults may serve as reservoirs for further
infection (1, 2). Although older studies suggested that pro-
tection against pertussis after natural infection was rela-
tively long lived (3), others suggest that protection after ei-
ther vaccination or natural infection may wane by young
adulthood (2, 4, 5). Vaccination with whole cell vaccines
provides good protection against childhood pertussis infec-
tion and has largely controlled whooping cough in indus-
trialized countries (3). In the United States, acellular vac-
cines comprised of purified pertussis antigens are now
replacing whole cell vaccines.
Despite many years of vaccine use, the nature of protec-
tive immunity to pertussis induced by either natural infec-
tion or vaccination remains poorly understood. Early clini-
cal trials of whole cell pertussis vaccines suggested that
protection occurred in the presence of high titers of agglu-
tinating antibodies, but in clinical trials of acellular vaccines
it has been difficult to define quantitative correlations be-
tween specific antipertussis antibody levels and protection
against disease (6–9). On the other hand, passive transfer of
various types of antipertussis antibodies has been shown to
protect against pertussis infection in animal models (10–14).
Mice genetically deficient in mature B cells given aerosol
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B Cell– and CD4
 
1
 
 T Cell–dependent Protective Immunity to 
 
B. pertussis
 
B
 
.
 
 pertussis
 
 infection develop a persistent infection that
never resolves but does not disseminate (15). In addition,
recent studies have demonstrated that pertussis-specific hu-
man (16) and murine (17, 18) T cells, particularly CD4
 
1
 
 T
cells, secrete IL-2 and IFN-
 
g
 
 in response to specific stimu-
lation. In a mouse model of respiratory infection, transfer
of these Th1-like cells resulted in bacterial clearance in the
apparent absence of antibodies (17). Further, after aerosol
infection, mice lacking IFN-
 
g
 
 did not control bacterial
growth well (19), and mice lacking IFN-
 
g
 
 receptors had
disease with aberrant organ pathology, atypical dissemina-
tion of bacteria outside of lungs, and occasional deaths (15).
Consistent with controversial reports suggesting that 
 
B
 
.
 
 per-
tussis
 
 survives, if not replicates, within murine (20), rabbit
(21), or human (21) macrophages, the latter results suggest
that cell-mediated immunity may play a significant role in
controlling pertussis infection.
To further define the fundamental basis of protective im-
munity to pertussis, we have used a mouse model of per-
tussis infection that mimics the severity of human disease.
Infection of adult mice with pertussis through an aerosol
chamber deposits bacteria on the ciliated epithelium of the
trachea and the bronchial tree; bacteria multiply and reach
peak numbers by days 7–10, and decline thereafter until
clearance 40–100 d later (22). On the other hand, infection
of mice younger than 19 d old is not controlled and results
in death after 
 
z
 
3 wk. Although infection of neonatal mice
is obviously of interest, it is difficult to obtain sufficient
cells or serum for comprehensive analysis from such young
mice. The long time course of primary infection clearance
in adult mice limits studies of secondary immunity, and im-
munodeficient mice do not clear primary infection (15,
19). Here, we have used intranasal immunization of various
mice with formalin-fixed 
 
B
 
.
 
 pertussis
 
 (FFBP)
 
1
 
 followed by
aerosol pertussis challenge to comprehensively evaluate the
relative contributions of T cells, B cells, and specific anti-
body to secondary protective immunity.
 
Materials and Methods
 
Mice. 
 
BALB/cAnNcR, BALB/c.
 
nu/nu
 
 (nude), C3H/HeJ,
and C57BL/6 mice were obtained from the Animal Production
Program, Division of Cancer Research Treatment, National
Cancer Institute. Total TCR knockout (KO) mice (
 
Tcr
 
b
 
2
 
Tcr
 
d
 
2
 
)
and CD4 KO mice, both on a B6/129 background, were pur-
chased from the Induced Mutant Resource of The Jackson Labo-
ratory. 
 
b
 
2-microglobulin
 
2
 
 and 
 
Igh6
 
2
 
 (
 
m
 
MT; reference 23) KO
mice, both on a C57B/6 background, were also purchased from
The Jackson Laboratory. JhD BL/6 mice (24) were obtained
from Gnotobiote Laboratory. Mice were purchased at 5 wk of
age and maintained in microisolator cages under specific patho-
gen-free conditions, fed autoclaved food and water ad libitum,
and routinely tested for common murine pathogens. In conduct-
ing the research described in this report, the investigators adhered
 
to a protocol approved by the Animal Care and Use Committee
of the Center for Biologics Evaluation and Research.
 
Bacteria and Antigens. 
 
Formalin-fixed antigens were prepared
as follows: 
 
B
 
.
 
 pertussis
 
 strains 18323 and Tohama I were grown on
Bordet-Gengou agar plates, and confluent lawns of bacteria were
harvested and transferred to Stainer Scholte media. After 36–48 h
of incubation (early stationary phase), bacteria were fixed by ad-
dition of formalin to a final concentration of 0.2% with gentle
shaking at 24
 
8
 
C overnight. The preparation was then washed in
PBS and resuspended to 440 
 
m
 
g protein/ml (as determined by
BCA protein assay; Pierce Chemical Co.) in PBS with 0.04% so-
dium azide as a preservative. 
 
Escherichia coli
 
 strain HB101 was
grown on LB plates, transferred to LB liquid media, and treated
as above.
Microspheres composed of poly(
 
dl
 
-lactide-co-glycolide) con-
taining FFBP whole cells, filamentous hemagglutinin (FHA),
pertussis toxoid, or pertactin (PRN) were prepared under De-
partment of Health and Human Services Public Health Service
contract no. 223-94-1237 by the Southern Research Institute.
The encapsulated microspheres were characterized and had prop-
erties similar to those described previously (25).
 
Immunizations.
 
Animals were lightly anesthetized with Meto-
fane inhalant anesthesia (Pittman Moore, Inc.) and intranasally
immunized by depositing the antigen in 25 
 
m
 
l PBS on the nares
as described previously (22). Mice were intranasally immunized
with two doses given 1 mo apart of 1–30 
 
m
 
g of formalin-fixed
bacteria or 1 or 10 
 
m
 
g microencapsulated pertussis antigens, as in-
dicated. Immunized animals were administered a 
 
B
 
.
 
 pertussis 
 
aero-
sol challenge 1 mo after the second immunization, unless other-
wise stated.
 
Aerosol Challenge.  B
 
.
 
 pertussis
 
 18323 at 10
 
9
 
/ml was adminis-
tered to mice as an aerosol for 30 min as described previously
(22). For each experiment, two mice were killed upon removal
from the aerosol chamber to assess the initial number of viable 
 
B
 
.
 
pertussis
 
 cells in the lungs. 7 d after the 
 
B
 
.
 
 pertussis
 
 challenge,
which is the peak of infection in unimmunized mice given an
aerosol pertussis challenge (26), lungs and tracheae of infected an-
imals were aseptically removed, homogenized in PBS, and plated
on Bordet-Gengou agar to determine the number of recoverable
bacteria. Plates incubated with 100 
 
m
 
l of undiluted homogenate
that had no 
 
B
 
.
 
 pertussis
 
 growth were scored as having 0.5 CFU/
100 
 
m
 
l; minimum level of detection of bacteria was therefore 1.4
log
 
10
 
 CFU in the lungs and 0.7 log
 
10
 
 CFU in the tracheae. Wil-
coxon analysis (two-sample test assuming equal variance) was
used to test bacterial recovery data for statistical significance.
 
Analysis of Antibody Response. 
 
Serum from mucosally immu-
nized mice was collected by bleeding anesthetized animals from
the brachial artery 1 mo after the last immunization. Bronchoal-
veolar lavage (BAL) fluid was collected by lavage of the lungs
with sterile PBS as described previously (26). Serum and BAL
fluid from immunized mice were analyzed for specific antibody as
described previously (26) using Immulon 1 plates coated with
pertussis antigens, serially diluted samples of sera or BAL fluid,
and development with alkaline phosphatase–conjugated goat
anti–mouse IgM, IgG, or IgA (Southern Biotechnology Associ-
ates, Inc.) and phosphatase substrate (Sigma-Aldrich). Specific an-
tibody titers were expressed as the reciprocal of the endpoint di-
lution, calculated by extrapolation to zero from the linear part of
the titration curve. Minimal IgM antibodies were detected at
these time points, and IgG titers are shown here as indicated.
 
Analysis of T Cell Responses.
 
C3H/HeJ mice were immu-
nized intranasally with two doses given 1 mo apart of 30 
 
m
 
g of
formalin-fixed bacteria, as above. To visualize the lymph nodes,
 
1
 
Abbreviations used in this paper:
 
 BAL, bronchoalveolar lavage; BKO, B cell
knockout; FFBP, formalin-fixed 
 
Bordetella pertussis
 
; FF 
 
E
 
.
 
 coli
 
, formalin-
fixed 
 
E
 
s
 
cherichia coli
 
; FHA, filamentous hemagglutinin; KO, knockout;
LOS, lipooligosaccharide; PRN, pertactin; PT, pertussis toxin. 
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mice were boosted with an additional dose of FFBP 4 d before
being killed, and 24 h before being killed the mice were injected
intraperitoneally with carbon soot encapsulated in lecithin (Thies
Technologies). Tracheobronchial and hilar lymph nodes were re-
moved, and T cells were enriched by passage through a nylon
wool column equilibrated with 10% fetal bovine serum in RPMI
1640. Eluted T cells were collected, and enrichment was assessed
by flow cytometry (see below). T cells were cultured at 2 
 
3 
 
10
 
5
 
per well in triplicate groups in RPMI 1640 supplemented with
10% fetal bovine serum (HyClone), 2 mM glutamine, 0.075% so-
dium bicarbonate, and 5 
 
3
 
 10
 
2
 
5
 
 M 2-ME (all purchased from
GIBCO BRL Life Technologies) in 96-well tissue culture plates
(Costar). Irradiated splenocytes (4 
 
3
 
 10
 
5
 
) were added as a source
of APCs, and FFBP or formalin-fixed 
 
E. coli
 
 (FF 
 
E
 
.
 
 coli
 
) was added
as antigen at a final concentration of 50 or 10 
 
m
 
g/ml. For deter-
mination of proliferation, 0.5 
 
m
 
Ci/well [
 
3
 
H]thymidine (New En-
gland Nuclear; 6.0 Ci/mmole specific activity) was added 2 d after
initiation of cultures and 16 h before harvesting and determina-
tion of incorporated radioactivity. Results are expressed as mean
cpm 
 
6
 
 SD of triplicate cultures. For detection of cytokines, simi-
lar cultures were established in 24-well plates, using 50 
 
m
 
g/ml
FFBP or FF 
 
E
 
.
 
 coli
 
 per well. Culture supernatants were harvested
at 48 h after initiation of cultures and were tested for the presence
of IFN-
 
g
 
, IL-4, and IL-10 using known standards and pairs of cy-
tokine-specific mAbs in an ELISA (BD PharMingen). In these
studies, cells from immunized C3H/HeJ mice (which are also
protected against aerosol challenge) were used to minimize back-
ground proliferation due to LPS recognition (particularly because
FF 
 
E
 
.
 
 coli
 
 was used as an irrelevant control).
 
Passive Transfer of Serum. 
 
Immune serum for passive transfer
was prepared by immunizing large groups of mice with two doses
of antigen intranasally 1 mo apart. Animals were bled at 4 wk af-
ter the second immunization, and the sera were pooled and
stored at 
 
2
 
70
 
8
 
C until use. Serum (2 ml) was injected intraperito-
neally into normal BALB/c mice 2 h before administration of a
pertussis aerosol challenge, as above. Lungs and tracheae were
plated out on days 7 and 8 after the challenge.
 
Adoptive Transfer of Immune B Cells.
 
Similar to T cell prepara-
tion (above), B cells were prepared from the draining lymph
nodes of lungs from mice immunized with two doses of forma-
lin-fixed bacteria given 1 mo apart, boosted 4 d before killing,
and injected intraperitoneally with carbon soot. Tracheobron-
chial and hilar lymph nodes were removed, and B cells were en-
riched by treatment with anti–mouse CD8a, anti-CD4, anti-
CD90, and anti–TCR-
 
g
 
/
 
d
 
 mAbs at a concentration of 10 
 
m
 
g/ml
for 30 min. After washing once with DMEM, cells were resus-
pended in 10% rabbit complement, incubated for 30 min at
37
 
8
 
C, and washed three times with 10 vol DMEM before trans-
fer. Purity of the cell population was determined using flow cy-
tometry analysis (see below), which routinely demonstrated that
enriched populations were 
 
.
 
90% B cells, with 
 
,
 
3% contamina-
tion with T cells. 1 mo after the second immunization, immu-
nized recipient 
 
m
 
MT or JhD BL/6 mice were given 2.5–4.5 
 
3
 
10
 
7
 
 B cells per animal intravenously in the lateral tail vein,
boosted intranasally with formalin-fixed bacteria 1 d after transfer
of B cells, and then challenged 2 wk later with an aerosol pertus-
sis infection.
 
Depletion of Mice with Anti-CD4 and Anti-CD8 Antibodies and
Flow Cytometry. 
 
To deplete CD4
 
1
 
 T cells, CD8
 
1
 
 T cells, or
both in vivo, immunized mice were treated intraperitoneally
with 1 mg of anti-CD4 mAb (clone GK1.5; rat IgG
 
2b
 
), 1 mg of
an anti-CD8 mAb (clone 2.43; rat IgG
 
2b
 
), or 500 
 
m
 
g of each on
days 
 
25 and 21 relative to aerosol pertussis challenge, as well as
on day 3 after challenge. Both mAbs were precipitated from as-
cites with 50% ammonium sulfate. Lymph node and spleen pop-
ulations from randomly chosen mice were analyzed for effective-
ness of depletion on the day of the pertussis challenge and at day
7 by flow cytometry using a FACScan™ (Becton Dickinson).
Cells were stained using a panel of mAbs including FITC–anti-
B220, PE–anti-CD4, PE–anti-CD8, PE–anti-CD11b, and PE–
anti–TCR-g/d (all purchased from BD PharMingen; optimal
staining concentrations determined separately) in both one- and
two-color staining protocols. Flow cytometry analysis of lympho-
cyte and spleen cells from the GK1.5- or 2.43-treated mice rou-
tinely demonstrated .95% depletion of T lymphocytes.
Results
Characterization of Protection Induced by Immunization with
FFBP, and Relationship to Specific Antibody Production and T
Cell Responses. To evaluate the protective capacity of
FFBP, adult BALB/c mice were immunized with two in-
tranasal doses given 1 mo apart of 1 or 10 mg FFBP in mi-
crospheres or 1 or 10 mg of unencapsulated FFBP and were
challenged by exposure to a B. pertussis aerosol 4 wk after
the last immunization. Animals given 1 or 10 mg microen-
capsulated FFBP exhibited a dramatic 4 log10 CFU reduc-
tion in bacterial recoveries from their lungs as well as a 3
log10 CFU reduction in bacterial recoveries from their tra-
cheae for both 1 and 10 mg doses compared with the bacte-
rial recoveries from the lungs of unimmunized infected
control mice (Table I). Mice administered two doses of 10
mg of unencapsulated FFBP intranasally completely cleared
the pertussis infection from both the lungs and tracheae in
this experiment. Protection by FFBP was dose dependent:
mice immunized with 1 mg of FFBP were not as well pro-
tected as those immunized with 10 mg. Thus, subsequent
experiments used 10–30 mg doses of unencapsulated FFBP
given intranasally. For comparison, a 30-mg dose of FFBP
is equivalent to z3 3 108 bacteria.
To evaluate the specificity of protection, the protective
capacity of other formalin-fixed bacteria was evaluated.
The strain used here for the aerosol challenge, B. pertussis
18323, may vary slightly in several respects from the B. per-
tussis type strain, Tohama I (27). BALB/c mice immunized
intranasally with 10 mg of FFBP derived from the strain
Tohama I and then challenged with B. pertussis strain 18323
had a similar reduction in bacterial recoveries from the
lungs and tracheae compared with animals immunized and
challenged with B. pertussis strain 18323, indicating that the
FFBP Tohama I strain provided comparable protection
against the 18323 challenge strain. However, mice immu-
nized with 10 mg FF E.coli and challenged with B. pertussis
18323 had no significant decrease in infection (Table I).
To examine the relationship between protection and an-
tibody levels, serum samples were obtained from FFBP-
immunized mice just before challenge and were analyzed for
the presence of various antipertussis antibodies (Table II).
The amount of circulating antibody to pertussis antigens at
the time of the pertussis challenge was compared with the
subsequent bacterial recoveries on day 7 after challenge in1844 B Cell– and CD41 T Cell–dependent Protective Immunity to B. pertussis
individual mice. All of the immunized mice had no detect-
able bacteria in lungs or tracheae at 7 d after challenge. In
contrast to our previous studies using microencapsulated
purified pertussis antigens, which elicited high levels of an-
tigen-specific IgG and IgA in serum and secretions (25),
two intranasal immunizations with 30 mg FFBP did not in-
duce consistent levels of specific serum IgG or IgA to puri-
fied pertussis antigens FHA, PRN, pertussis toxin (PT), li-
pooligosaccharide (LOS), or fimbriae (Table II). In studies
of .30 individual animals, occasional small IgG serum an-
tibody responses to all individual antigens were observed
(data not shown). However, all animals immunized pro-
duced an excellent serum IgG antibody response to pertus-
sis whole cell lysate, although no measurable levels (,1/50)
of specific serum IgA to pertussis antigens were observed.
Analysis of BAL samples of similarly immunized mice
showed that few animals produced antibody responses in
the lung to the purified antigens, but when these lung lav-
age samples were reacted with whole cell lysate, all animals
had strong specific IgG (1:120 6 45) and IgA (1/450 6 60)
titers.
The ability of various antibody preparations, including
one shown previously to transfer protection (25), to protect
mice against a B. pertussis infection by passive immunization
was then evaluated. As shown in Table III, mice that re-
ceived the serum antibody to the microsphere combination
completely cleared the infection in both the lungs and tra-
cheae by 7 d after the challenge. In contrast, animals that
Table I. Bacterial Recoveries after B. pertussis Aerosol Challenge of Mice Immunized Intranasally with FFBP or FF E. coli
Lungs Tracheae
Group Log10 CFU No. infected/total Log10 CFU No. infected/total
10 mg B. pertussis microspheres 2.25 6 1.29* 2/6 1.23 6 0.76* 2/6
1 mg B. pertussis microspheres 2.30 6 0.73* 5/6 1.33 6 0.43* 5/6
10 mg FFBP 18323 1.40 6 0.00* 0/6 0.70 6 0.00* 0/5
1 mg FFBP 18323 4.52 6 0.26* 6/6 1.75 6 0.33* 5/5
10 mg FFBP Tohama I 1.74 6 0.55* 6/6 0.91 6 0.43* 6/6
10 mg FF E. coli 5.90 6 0.35 6/6 4.22 6 0.50 6/6
Infected controls 6.42 6 0.27 6/6 4.88 6 0.22 6/6
Mice were immunized twice intranasally as indicated and challenged with B. pertussis. Values shown are the mean 6 SD log10 CFU 1 wk after aerosol
challenge. Results from one representative experiment of three experiments of similar design are shown.
*P , 0.005 compared with unimmunized infected controls.
Table II. Relationship between Serum Antibody Response and Bacterial Clearance in FFBP-immunized Mice
Bacterial recovery Serum IgG antibodies to:*
Animal no. Lungs Tracheae FHA PRN PT LOS Fimbriae Whole cell lysate
log10 CFU
1-1 Sterile Sterile – – – – – 19,000
1-2 Sterile Sterile – 1,000 – – – 10,000
1-3 Sterile Sterile – 4,000 – – – 40,000
1-4 Sterile Sterile 16,000 1,000 – – – 70,000
1-5 Sterile Sterile 2,500 1,000 – – – 40,000
1-6 Sterile Sterile 1,500 – – – – 90,000
1-7 Sterile Sterile 800 – – – – 40,000
1-8 Sterile Sterile – 800 – – – 40,000
Controls 6.49 4.94 – – – – – –
Mice were immunized twice intranasally with FFBP and bled 1 mo later, and all mice were then challenged with B. pertussis. Values shown are the
mean 6 SD log10 CFU 1 wk after aerosol challenge, or were below the limit of detection and designated as sterile. Results from 8 individual mice
of .30 individual mice assessed are shown.
*Values shown are endpoint titers. A dash indicates that no specific antibody was detected (titer of ,1:50); no antigen-specific serum IgA was de-
tected in any sample.1845 Leef et al.
received 2 ml of serum from mice immunized with 30 mg
of FFBP did not have a significant reduction in coloniza-
tion in the lungs, compared with levels of bacteria in in-
fected control mice or mice given normal mouse serum.
This immune serum contained high amounts of antibodies
to pertussis whole cell lysates, as well as minimal levels of
antibodies to FHA (Table III footnote).
To determine whether antigen-specific T cell responses
were present in FFBP-immunized mice, purified T cells
were prepared from mice immunized intranasally with
FFBP and cultured with a source of APCs as well as with
FFBP as antigen. FFBP-stimulated T cells proliferated vig-
orously (Fig. 1); no proliferation above background was
observed in cultures stimulated with an irrelevant antigen
(FF E. coli) or in cultures lacking APCs. Further, T cells
from unimmunized mice did not proliferate in response to
either antigen (Fig. 1). To examine the cytokines produced
by such pertussis-specific T cells, supernatants were har-
vested from comparable parallel cultures. By 48 h, superna-
tants from cultures containing pertussis-immune T cells,
FFBP, and APCs contained 2.2 6 0.3 ng/ml IFN-g, but
levels of IL-4 and IL-10 in the same supernatants were be-
low the limit of detection (50 pg/ml and 30 pg/ml, respec-
tively). All three cytokines were undetectable in all other
control cultures (50 pg/ml for IFN-g).
Defective Generation of Protection in B Cell KO Mice, and Re-
constitution of Protection by Transfer of Primed B Cells.  We
further assessed the requirement for B cell–dependent pro-
tection after immunization with FFBP or microspheres by
immunizing  mMT B cell KO mice (BKO [23]) and
matched wild-type control C57BL/6 mice intranasally with
FFBP. B. pertussis aerosol challenge was administered 1 mo
after the second immunization. Both groups of wild-type
control mice, immunized with either microencapsulated
pertussis antigens or with FFBP, had a substantial reduction
in infection in the lungs and complete clearance of infection
from the tracheae (Fig. 2). These immunocompetent
Table III. Bacterial Recoveries after Passive Transfer of Serum
Serum from mice 
immunized with:* n Lungs Tracheae
log10 CFU‡
Microsphere combination 5 1.40 6 0.00 0.70 6 0.00
30 mg FFBP 6 5.65 6 0.36 3.62 6 0.20
30 mg FF E. coli 5 6.26 6 0.24 4.38 6 0.16
Normal mouse serum 6 6.69 6 0.15 4.88 6 0.14
Infected controls 7 6.32 6 0.46 4.73 6 0.30
*Mice received 2 ml of serum intraperitoneally as indicated 2 h before
individual serum samples were obtained, then were challenged with B.
pertussis. Endpoint serum IgG titers of the pooled sera injected intra-
peritoneally (2 ml) were as follows. For the anti–microsphere combina-
tion serum: anti-FHA and anti-PT, 70,000 each, and anti-PRN,
45,000; for the anti–30 mg FFBP serum: anti-FFBP, 40,000, and anti-
FHA, 2,400. After transfer and immediately before challenge, the geo-
metric mean serum titers in recipient mice were as follows. For the
anti–microsphere combination serum: anti-FHA, 41,000, anti-PT,
36,000, and anti-PRN, 37,000; for the anti-FFBP serum: anti-FFBP,
36,000, and anti-FHA, 1,100. Results from one representative experi-
ment of two experiments of similar design are shown.
‡Values shown are the mean 6 SD log10 CFU 1 wk after aerosol chal-
lenge.
Figure 1. Antigen-specific proliferation of T cells in FFBP-immunized
mice. Cells obtained from the draining lymph nodes of FFBP-immunized
mice were cultured in the presence or absence of APCs, FFBP at the in-
dicated doses, or FF E. coli at the indicated doses. Proliferation was as-
sessed by overnight pulse of [3H]thymidine added at day 2 after initiation
of cultures and harvest on day 3. Mean cpm 6 SD of triplicate cultures,
from FFPB-immunized (white bars) or unimmunized (gray bars) are
shown. T cells used in this experiment were 97% CD41CD81 T cells and
0.9% B2201 cells.
Figure 2. Protection after immunization with FFBP in B cell KO
mice. Wild-type C57BL/6 mice (d) and C57.Igh62 B cell KO mice (s)
were immunized twice with either pertussis antigens in microspheres or
with FFBP, and were challenged 1 mo later along with unimmunized
wild-type or BKO control mice (infected controls). Bacterial recoveries as
log10 CFU from lungs and tracheae 1 wk after pertussis infection are
shown. Circles represent results from individual mice; bars represent me-
dian values. Results from one representative experiment of three experi-
ments of similar design are shown. By Wilcoxon analysis, median recov-
eries of bacteria in both lungs and tracheae are significantly different
between wild-type mice and BKO mice immunized with microspheres
(P , 0.05) or with FFBP (P , 0.05). Median bacterial recoveries are also
significantly different between infected control wild-type mice and wild-
type mice vaccinated with either microspheres (P , 0.05) or FFBP (P ,
0.05). Median bacterial recoveries were not significantly different be-
tween infected BKO control mice and immunized BKO mice (P  .
0.05), or between infected wild-type control mice and infected BKO
control mice in either lungs or tracheae (P . 0.05).1846 B Cell– and CD41 T Cell–dependent Protective Immunity to B. pertussis
FFBP-immunized animals had average serum IgG titers
against whole cell lysate of 47,500. Immunocompetent
mice immunized with the microsphere combination had
high serum titers against all three pertussis antigens (FHA,
50,000; PT, 100,000; PRN, 50,000). By comparison, BKO
mice immunized with either microencapsulated antigens or
with FFBP had no reduction in bacterial recoveries com-
pared with the unimmunized infected control mice, and
had no detectable levels of serum antibody to pertussis anti-
gens (,1:50).
To assess the relative contribution of B cells versus spe-
cific antipertussis antibodies to clearance of pertussis infec-
tion, reconstitution experiments were performed. Because
large quantities of anti-FFBP antibody had little impact on
bacterial recoveries even in intact wild-type mice (Table
III), only transfer of B cells was studied in BKO mice. Two
types of B cell–deficient mice, both JhD mice (experiment
1; reference 24) derived by targeted deletion of the Jh re-
gion of the IgM heavy chain, and mMT mice (experiments
2 and 3; reference 23) derived by targeted deletion of the m
region, were studied in these experiments. B cells were
prepared from draining lymph nodes of mice immunized
with two doses of FFBP intranasally, and were transferred
to recipient mice that were also immunized twice with
FFBP intranasally before transfer. To stimulate engraft-
ment, all mice were given a third immunization with FFBP
intranasally 1 d after B cell transfer, then were challenged 2
wk later. Of particular note, although BKO mice immu-
nized with FFBP had no reduction in colonization after a
pertussis challenge (Fig. 2), similar BKO mice developed a
significant ability to control an infection if immunized
three times with FFBP (2 log10 CFU reduction; Fig. 3).
This was despite having no detectable specific antibody at
the time of challenge, as expected (Table IV). Adoptive
transfer of primed B cells obtained from the draining
lymph nodes of vaccinated immunocompetent C57B/6
mice then enabled similarly immunized animals to com-
pletely clear the infection in two of three experiments per-
formed (Fig. 3). BKO mice immunized with FFBP were
completely protected if given between 3–4.5 3 107 FFBP
primed B cells (experiments 1 and 2), but not if given only
2.5 3 107 primed B cells (experiment 3). In experiments (1
and 2) in which reconstitution was effective, serum anti-
body titers to pertussis whole cell lysate at the time of chal-
lenge were evaluated in individual mice. Very low titers
were observed in all cases except for groups of immunized
wild-type control mice, and there was no correlation be-
tween production of serum antipertussis antibodies and
clearance of bacteria (Table IV). Notably, 7/12 (58%) of
the KO mice that received primed B cells in the two posi-
tive experiments had very low but detectable serum anti-
body levels, but 5:12 (42%) had undetectable levels of spe-
cific antibodies and cleared infection (Table IV). Specific
serum antibody titers did not increase after challenge (foot-
note to Table IV).
Defective Generation of Protection in T Cell KO Mice. To
assess the requirement for T cells in the mechanism of im-
mune clearance after a mucosal immunization, both adult
BALB/c athymic nu/nu mice and mice lacking all TCRs
(Tcrb2Tcrd2) were studied. B6129/J.Tcrb2Tcrd2 mice that
lack all mature T cells and control B6129/J F2 mice were
given two immunizations intranasally with 30 mg of FFBP
and an aerosol B. pertussis challenge 1 mo later, and bacte-
rial recoveries in lungs were evaluated. As shown in Fig. 4
Figure 3. Reconstitution of protection after immunization with FFBP in B cell KO mice by transfer of FFBP-primed B cells. Wild-type C57BL/6
mice (d) and JhD or mMT BKO mice (BKO mice indicated by s) were immunized twice with FFBP. B cells were prepared from similar mice immu-
nized twice with FFBP or FF E. coli as indicated, and were transferred to immunized BKO mice that were then given a third immunization with FFBP
and an aerosol challenge with B. pertussis. Bacterial recoveries as log10 CFU from lungs 1 wk after pertussis infection for all three individual experiments
are shown; similar results were seen in bacterial recoveries from tracheae (data not shown). Circles represent results from individual mice; bars represent
median values. Results of all three individual experiments are shown. By Wilcoxon analysis, median recoveries of bacteria in lungs are significantly differ-
ent between wild-type mice and BKO mice immunized three times with FFBP (P , 0.05; Wilcoxon analysis), as are median bacterial recoveries be-
tween reconstituted and nonreconstituted BKO mice in experiments 1 and 2 (P , 0.05). Median bacterial recoveries are also significantly different be-
tween infected control wild-type mice and wild-type mice vaccinated with FFBP in all three experiments (P , 0.05). In experiment 2, median bacterial
recoveries were not significantly different between infected wild-type control mice or infected BKO control mice in either lungs or tracheae (P . 0.05).
In experiment 2, median bacterial recoveries were not significantly different between infected control mice and either FF E. coli–immunized mice or
BKO mice that were reconstituted with FF E. coli–primed B cells (P . 0.05).1847 Leef et al.
A, control C57BL/6 animals were protected against a per-
tussis challenge; however, the immunized TCR KO mice
were not protected at all. Similar results were observed in
bacterial recoveries in the tracheae (data not shown).
Similarly, athymic BALB/c.nu/nu mice lacking TCR-
a/b1 T cells and control euthymic BALB/c mice were
immunized with 30 mg of FFBP and challenged. Unlike
immunized normal mice, immunized BALB/c.nu/nu mice
were unable to clear the infection at 1 wk and had bacterial
recoveries similar to the unimmunized BALB/c.nu/nu and
unimmunized BALB/c mice (Fig. 4 B). Similar results
were observed in the tracheae (data not shown).
The long-term outcome of immunization of BALB/
c.nu/nu mice with FFBP was studied further as well. Here,
immunized mice were challenged and assessed for bacterial
burdens at 3 and 5 wk (rather than 1 wk) after challenge.
Table IV. Anti–B. pertussis Antibody Titers in Reconstituted BKO Mice
Group Experiment 1* No. responding/total Experiment 2* No. responding/total
C57BL/6 immunized FFBP 58,000 6 15,000 11/11 50,000 6 11,000 6/6
C57BL/6 immunized FF E. coli ,50 0/6 ,50 0/5
C57BL/6 infected controls ,50 0/10 ,50 0/6
BKO immunized FFBP ,50 0/6 ,50 0/7
BKO immunized FFBP;
FFBP-primed B cells transferred 266‡ 3/5 675‡ 4/7
BKO immunized FF E. coli ND – ,50 0/6
BKO immunized FF E. coli;
FF E. coli–primed B cells transferred ND – ,50 0/6
BKO infected controls ND –
,50 0/4
*Mice were treated as described in the legend to Fig. 3, and individual serum samples were obtained immediately before aerosol pertussis challenge.
Geometric mean titers 6 SD of IgG serum antibodies tested by ELISA on plates coated with FFBP are shown for the groups of mice in Fig. 3. For
numbers of responding mice, responses are designated as positive for titers of 1:50 or greater. Data from experiment 3 is not shown, as reconstitution
with this lower number of B cells did not result in bacterial clearance. All animals had serum IgG titers of ,50 for FHA, PT, and PRN, except for
the C57BL/6 immunized FFBP group in experiment 2. 2/6 mice had anti-PRN IgG titers of 6,000 and 11,000.
‡Individual serum IgG titers for experiment 1 immediately before aerosol pertussis challenge were 200, 300, ,50, 300, and ,50. Individual titers for
experiment 2 were ,50, ,50, 300, 200, 1,500, ,50, and 700. Individual serum IgG titers 1 wk after challenge (for the same mice, listed in the same
order) for experiment 1 were 500, 300, ,50, 200, and ,50. Individual titers for experiment 2 were ,50, ,50, 600, ,50, 600, 400, and ,50.
Figure 4. Protection after immunization with FFBP in T cell–deficient mice. Wild-type B6/129 F2 or BALB/c mice, as indicated (d) and B6/129
Tcrb2Tcrd2 mice or BALB/c.nu/nu mice, as indicated (s) were immunized twice with FFBP, then challenged with B. pertussis. Bacterial recoveries as
log10 CFU from lungs 1 wk (A and B) or 3 and 5 wk (C) after pertussis infection are shown. Circles represent results from individual mice; bars represent
median values. Results of all three individual experiments are shown. By Wilcoxon analysis, median recoveries of bacteria in lungs are significantly differ-
ent between wild-type mice and T cell KO or nu/nu mice vaccinated with FFBP (P , 0.05). Median bacterial recoveries are also significantly different
between infected control wild-type mice and wild-type mice immunized with FFBP (P , 0.05). Median bacterial recoveries were not significantly dif-
ferent between either type of infected control mice and immunized T cell KO mice (A; P . 0.05), nor between infected control mice and FFBP-immu-
nized nu/nu mice (B; P . 0.05). Median bacterial recoveries were significantly different between wild-type BALB/c mice and nu/nu mice, both infected
and immunized, at both time points (C; P , 0.05).1848 B Cell– and CD41 T Cell–dependent Protective Immunity to B. pertussis
At these later time points, the pertussis infection not only
persisted but increased in both unimmunized BALB/c.nu/nu
and immunized BALB/c.nu/nu mice (Fig. 4 C). In con-
trast, all immunized BALB/c mice had cleared the infec-
tion completely at 3 wk, and even unimmunized infected
control BALB/c mice had almost completely resolved the
infection at week 5. Groups of eight animals, both immu-
nized and unimmunized, were also challenged and ob-
served to determine survival. As observed previously (17),
both groups of BALB/c.nu/nu mice began dying at 5 wk.
By 11 wk after the aerosol challenge, only one of eight of
each of these two groups survived, in contrast to BALB/c
immunized and control mice, which all survived. At that
time, lungs from the two surviving BALB/c.nu/nu mice
were assessed for bacterial burden, and had bacterial recov-
eries of 7.3 and 7.5 log10 CFU, respectively.
To assess the contribution of T cell subpopulations to
the expression of protection, BALB/c mice were immu-
nized intranasally with 30 mg of FFBP and depleted of
CD41 cells, CD81 cells, or both and then challenged.
Spleens and tracheobronchial lymph nodes from treated
mice analyzed by flow cytometry for depletion of T cells at
the time of challenge contained ,2% residual CD41 and/
or CD81 T cells, as appropriate. Control unimmunized
BALB/c mice that were challenged or depleted of both
CD41 and CD81 T cells before challenge each averaged
6.6 log10 CFU in their lungs. In contrast, immunized and
challenged intact mice, as well as CD8-depleted mice, ex-
hibited a 4 log or greater average reduction in colonization
(Fig. 5). Bacterial burdens in both lungs and tracheae of
mice immunized and then depleted of CD41 cells, or total
T cells, were higher than in immunized mice but lower
Figure 5. Protection after immunization
with FFBP in mice depleted in vivo  of
CD41 T cells, CD81 T cells, or both.
BALB/c mice were immunized twice with
either antigens in microspheres or with
FFBP. 5 d before aerosol pertussis challenge,
in vivo depletion of T cell subsets was initi-
ated, as indicated. Bacterial recoveries as
log10 CFU from lungs and tracheae 1 wk af-
ter pertussis infection are shown. Results
from both experiments, of similar design,
are shown; circles represent results from in-
dividual mice (d, experiment 1; s; experi-
ment 2), and bars represent median values.
By Wilcoxon analysis, median recoveries of
bacteria in both lungs and tracheae are sig-
nificantly different between nondepleted
mice and either CD4-depleted mice or
CD4/CD8–depleted mice immunized with
FFBP for both lungs and tracheae (P  ,
0.05). Median bacterial recoveries are also
significantly different between infected control mice and nondepleted mice immunized with FFBP (P , 0.05). Median bacterial recoveries are also sig-
nificantly different between infected control (either nondepleted or CD4/CD8–depleted) mice and CD4-depleted mice immunized with FFBP (P ,
0.05). Median bacterial recoveries were not significantly different between nondepleted immunized mice and CD8-depleted immunized mice (P .
0.05), nor between infected wild-type control mice and infected CD4/CD8–depleted control mice in either lungs or tracheae (P . 0.05).
Figure 6. Protection after immunization
with FFBP in mice genetically lacking
CD41 T cells or CD81 T cells. B6/129 F2
mice (background strain for CD4 KO mice;
A), C57BL/6 mice (background strain for
b2m2 KO; B), CD4 KO mice, and b2m2
KO mice (CD8-deficient mice) were im-
munized twice with FFBP and challenged
with  B. pertussis. Bacterial recoveries as
log10 CFU from lungs 1 wk after pertussis
infection are shown. Results from one rep-
resentative experiment of two experiments
of similar design are shown. d indicates re-
sults from individual wild-type mice, and s
indicates results from individual KO mice;
bars represent median values. By Wilcoxon
analysis, median recoveries of bacteria in
both lungs and tracheae are significantly
different between wild-type B6/129 F2 mice and CD4 KO mice immunized with FFBP (A; P , 0.05). Median bacterial recoveries are also signifi-
cantly different between infected control mice and wild-type mice immunized with FFBP (A and B; P , 0.05), and between infected control CD4 KO
mice and immunized CD4 KO mice (A). Median bacterial recoveries are not significantly different between wild-type mice and b2m2 KO (CD8-defi-
cient) immunized mice (P . 0.05), or between infected wild-type control mice or the respective infected KO control mice (A and B; P . 0.05).1849 Leef et al.
than in unimmunized mice; thus, CD4-depleted mice did
not clear the infection effectively.
Further experiments were performed using CD4 KO or
b2-microglobulin KO mice, which lack mature CD81
cells. CD4 KO mice and appropriate control B6/129 F1
mice were immunized twice intranasally with FFBP and
challenged. Fig. 6 shows that immunized control animals
averaged a 5 log10 CFU reduction in bacterial recoveries
compared with the unimmunized infected controls or with
unimmunized infected CD4 KO mice. However, the im-
munized CD4 KO mice had only a 1 log10 CFU average
decrease in bacterial recovery from the lungs. In contrast,
when b2-microglobulin KO mice and control C57BL/6
mice were similarly immunized, the KO mice were as well
protected as the control mice (Fig. 6).
Discussion
Understanding of the nature of protective immunity to
B. pertussis is of interest not only for knowledge of basic
mechanisms, but also in designing vaccine strategies. Here,
we show that similar to natural infection, protection in-
duced by intranasal immunization with FFBP was dose de-
pendent and specific for pertussis, but not limited to one
pertussis strain (Table I). Although specific antipertussis an-
tibodies were detected using whole bacteria as antigen,
minimal amounts of antibodies specific for major pertussis
antigens were detected (Table II), and transfer of large
amounts of anti-FFBP antibodies had minimal impact on
bacterial burdens after aerosol pertussis challenge, even in
normal wild-type mice (Table III). Antigen-specific, per-
tussis-responsive T cells that proliferated and produced
IFN-g but not IL-4 or IL-10 were readily detected in the
draining lymph nodes after intranasal immunization with
FFBP (Fig. 1; Results text), which are most likely CD41
Th1-like T cells. However, intranasal immunization of
BKO mice with FFBP did not lead to development of pro-
tective immunity, as assessed by clearance of bacteria, after
aerosol challenge (Fig. 2). Surprisingly, protection in BKO
mice was readily reconstituted by transfer of pertussis-
immune B cells shortly before challenge (Fig. 3). Similarly,
immunization of mice lacking all T cells (Fig. 4) or lacking
CD41 T cells (Figs. 5 and 6) did not lead to protection
against aerosol challenge; in contrast, CD8-deficient mice
(Figs. 5 and 6) were protected. Thus, the results presented
here indicate that pertussis-specific B cells and CD41 T
cells, but not CD81 T cells, are critical to the optimal gen-
eration and expression of secondary protective immunity to
pertussis after aerosol immunization with whole formalin-
fixed bacteria.
The relative contributions of CD41 and CD81 T cells
were examined using two methods: study of immunized
and challenged normal mice that were depleted of T cell
subpopulations, and study of immunized and challenged
KO mice. Both approaches lead to the same conclusion.
Neither CD8-depleted mice nor b2-microglobulin KO
mice, which lack mature CD81 T cells, differed from intact
mice in their ability to control aerosol pertussis challenge
after immunization with FFBP (Figs. 5 and 6). In fact, the
CD8 depletion experiments serve as an internal control
demonstrating that the depletion manipulations did not in
and of themselves alter the outcome of infection after im-
munization and challenge. In contrast, immunized CD4
KO mice were completely unable to control infection,
whereas depletion of CD41 T cells after immunization but
before challenge compromised the degree of protection but
did not ablate it entirely. Immunized wild-type mice de-
pleted of CD41 T cells just before challenge had specific
antibodies just as normal control mice, and thus the pres-
ence of specific antibodies at the time of challenge was ap-
parently insufficient for optimal protection in CD4-depleted
mice.
These results are consistent with other studies also indi-
cating crucial roles for T cells in general and CD41 T cells
in particular. To our knowledge, this is the first report of
the consequences of pertussis immunization and aerosol
challenge of CD4 or CD8 KO mice, and we are not aware
of studies comprehensively investigating the course of pri-
mary aerosol pertussis infection in CD4 or CD8 KO mice.
Previous studies clearly indicate that athymic nu/nu mice,
which lack all a/b1 T cells, exhibit chronic infection after
primary aerosol pertussis infection and die beginning at z5
wk after infection (references 17, 19; Fig. 4). Similarly, scid
mice, which lack all T cells as well as B cells, succumb to
chronic pertussis infection beginning at z3 wk after pri-
mary aerosol infection (19). Chronic infection in nu/nu
mice was reversed by transfer of immune T cells (17), al-
though the subpopulation involved in reconstitution of
nu/nu mice was not determined. In a different experimental
design, transfer of immune, pertussis-specific CD41 T cells
cleared primary infection in sublethally irradiated normal
BALB/c mice in the apparent absence of specific antibody
production, but bacterial clearance was not affected by
transfer of immune, pertussis-specific CD81 T cells (17).
Similar to results presented here using T cells from intrana-
sally immunized mice (Fig. 1; Results text), CD41 immune
T cells from mice given either a primary aerosol infection
(17, 18, 28) or immunized with fixed pertussis whole cell
preparations (18) also secreted IFN-g and IL- 2 in vitro in
response to pertussis. Other studies clearly indicate that
IFN-g is critical to the appropriate control of bacterial dis-
semination, pathology, and bacterial clearance after aerosol
pertussis infection of adult mice (15, 19). Further, periph-
eral blood mononuclear cells from pertussis-infected or
convalescent children produced IFN-g but not IL-5 in
vitro in response to stimulation by heat-killed pertussis bac-
teria, and thus appear to have a Th1-like phenotype (16).
Taken together, both previous data as well as the data pre-
sented here strongly indicate that CD41 T cells contribute
to protective immunity against pertussis through elabora-
tion of Th1-like cytokines and expression of cell-mediated
immunity, not just through functioning as helper cells in
promoting specific antipertussis antibody production.
Mice immunized with FFBP intranasally completely
cleared a subsequent pertussis aerosol challenge from tra-
cheae and lungs, but there was no correlation between lev-1850 B Cell– and CD41 T Cell–dependent Protective Immunity to B. pertussis
els of antibody to purified pertussis antigens (including
those used in acellular pertussis vaccines) such as FHA,
PRN, PT, LOS, or fimbriae and clearance of bacteria (Ta-
bles I and II). As seen previously in mice given subcutane-
ous (29) or intranasal (30) whole cell pertussis vaccines, im-
munized mice did have pertussis-specific antibodies in both
serum and lung lavage samples as assessed using whole bac-
teria in the ELISA (Table II; Results text) that exceed levels
found in naturally infected mice (17, 18, 28). Nonetheless,
passive transfer of a large (2 ml) volume of immune serum
obtained after immunization intranasally with FFBP had
minimal effects on bacterial burdens even in normal recipi-
ent mice after aerosol challenge. This is despite the fact that
serum antibody titers against FFBP in recipient mice were
similar to those of intact mice at the time of challenge (Ta-
ble III footnote). Similarly, in previous studies, transfer of
serum from convalescent pertussis-infected mice to normal
adult mice followed by aerosol pertussis infection had a
minimal impact on the uptake or early growth of pertussis
in lungs, and no effect on the time course of clearance (17).
Further, protection against aerosol pertussis challenge was
demonstrated here in the apparent absence of pertussis-spe-
cific antibodies, in that reconstituted BKO mice exhibited
maximal protection but had either minimal or no detectable
levels of serum antibodies (Fig. 3; Results text); similarly,
mice that received immune CD41 T cells had no detectable
serum antipertussis antibodies, but cleared aerosol challenge
(17). Also of note are studies indicating that mice given pri-
mary aerosol pertussis infection exhibited T cell–prolifera-
tive responses and bacterial clearance well before specific
antipertussis antibodies were detected in serum (17, 28).
Obviously, such results are in contrast to numerous stud-
ies demonstrating that passive transfer of pertussis-specific
antibodies, especially when produced by immunization
with purified pertussis antigen or acellular vaccines, are able
to protect against pertussis infection (10–14). We cannot
exclude the possibility that undetectable pertussis-specific
antibodies, produced locally after transfer of primed B cells
and/or accelerated with help from primed CD41 T cells
upon challenge, are responsible for the observed reconsti-
tution of protection (Fig. 3; Table IV), but we believe this
is very unlikely to be the primary explanation for several
reasons, including the relatively small challenge dose as well
as the rapid time course of clearance. Further, BKO mice
given three doses exhibited intermediate protection (Fig.
3), a situation in which no antibodies could be made.
Other results suggested that BKO mice vaccinated intra-
peritoneally with either whole cell pertussis vaccine or acel-
lular pertussis vaccines have diminished T cell activity (31).
However, our results suggest that T cell function in these
intranasally immunized BKO mice was not irreversibly
compromised, or at least was still sufficient for effectiveness;
importantly, reconstitution readily resulted in rapid clear-
ance of bacteria (Fig. 3). Under these circumstances, pro-
duction of specific antibodies was minimal, not increased
by challenge, and indeed undetectable in the serum of 40%
of successfully reconstituted BKO mice (Fig. 3; Table IV;
Results text). Finally, we cannot envision a relationship be-
tween the recently described defect in the development of
intestinal M cells in BKO mice (32) and the results seen
here, especially because reconstitution restored clearance
within 7 d after challenge. As has been proposed for the in-
tracellular bacterium Francisella tularensis live vaccine strain
(33), we interpret these experiments as indicating that im-
munity to pertussis, as generated by resolution of natural
infection or by intranasal immunization with whole bacteria,
involves a contribution from B cells in significant non–anti-
body-related roles. Although specific antipertussis antibod-
ies may certainly contribute to protection when available,
specific antibodies alone were not sufficient for optimal
protection (e.g., Fig. 5); conversely, optimal protection is
readily demonstrated in the apparent absence of specific an-
tibodies (e.g., Fig. 3). This in turn may explain the diffi-
culty in establishing definitive quantitative serological cor-
relates of protection in pertussis vaccine trials (6–9).
The specific effector activities provided by B cells await
future study, and there are several obvious candidates.
These include a role in antigen presentation to immune T
cells, B cell production of cytokines, B cell interaction with
other cells such as macrophages or natural killer cells, and B
cell regulation of appropriate cell trafficking (e.g., through
production of chemokines). Obviously, not all of these
possibilities are mutually exclusive, and in fact it is likely
that several different effector mechanisms, including anti-
body production, are involved in the dependence of pro-
tective immunity to pertussis on mature B cells. The appar-
ent requirement for pertussis-primed B cells, at least with
the numbers of cells transferred here, suggests that an anti-
gen-specific activity such as optimization of antigen presen-
tation may be the most likely function provided by B cells.
On the other hand, other studies of recirculation patterns
of murine lymphocyte populations after intravenous trans-
fer have found that very few transferred cells reach lung tis-
sue (34–36), raising the interesting possibility that the B
cell–dependent activity is operative at a distance from the
site of infection and involves production of soluble media-
tors such as chemokines and cytokines.
These studies also again raise the controversial concept of
intracellular localization of pertussis in macrophages or
other cells (20, 21, 37), and may be consistent with the no-
tion that part of the infection is extracellular and part in-
volves intracellular infection of cells such as alveolar macro-
phages. Further investigation into this particular possibility
appears to be well justified. Nonetheless, taken together,
our studies strongly indicate that specific secondary protec-
tive immunity to pertussis is mediated by a combination of
specific antipertussis antibodies, B cell function (other than
antibody production), and CD41 T cell–mediated immu-
nity, including production of Th1-like cytokines. Stimula-
tion of all these components may be the appropriate goal of
vaccine development, and not all components may be in-
voked by vaccination with current acellular pertussis vac-
cines.
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